blood cancer diagnostic products based on microarray platforms Search Results


blood cancer diagnostic products based on microarray platforms  (SkylineDX)
90
SkylineDX blood cancer diagnostic products based on microarray platforms
Market size of the global cancer diagnosis by technology platform (Unit: million $) [ <xref ref-type= 7 ]" width="250" height="auto" />
Blood Cancer Diagnostic Products Based On Microarray Platforms, supplied by SkylineDX, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blood cancer diagnostic products based on microarray platforms/product/SkylineDX
Average 90 stars, based on 1 article reviews
blood cancer diagnostic products based on microarray platforms - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Market size of the global cancer diagnosis by technology platform (Unit: million $) [ <xref ref-type= 7 ]" width="100%" height="100%">

Journal: Biomaterials Research

Article Title: The market trend analysis and prospects of cancer molecular diagnostics kits

doi: 10.1186/s40824-017-0111-9

Figure Lengend Snippet: Market size of the global cancer diagnosis by technology platform (Unit: million $) [ 7 ]

Article Snippet: SkylineDx is a company that branched off from the Erasmus University Medical Center (Rotterdam, Netherlands) that has developed and commercialized blood cancer diagnostic products based on microarray platforms.

Techniques: Biomarker Discovery, Microarray, Multiplex Assay

The global market size for molecular diagnostics blood cancer diagnoses (Unit: million $) [ <xref ref-type= 7 ]" width="100%" height="100%">

Journal: Biomaterials Research

Article Title: The market trend analysis and prospects of cancer molecular diagnostics kits

doi: 10.1186/s40824-017-0111-9

Figure Lengend Snippet: The global market size for molecular diagnostics blood cancer diagnoses (Unit: million $) [ 7 ]

Article Snippet: SkylineDx is a company that branched off from the Erasmus University Medical Center (Rotterdam, Netherlands) that has developed and commercialized blood cancer diagnostic products based on microarray platforms.

Techniques: Microarray, Multiplex Assay